Kong, Chuize <br/><br/>
Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome.  [electronic resource] 

 -  Urology  Feb 2005 
 - 395-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1527-9995 
<br/><br/><label>Standard No.: </label>10.1016/j.urology.2004.09.041  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Animals<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis<br/>Carcinoma, Transitional Cell--blood supply<br/>Cisplatin--administration & dosage<br/>Combined Modality Therapy<br/>Cyclohexanes<br/>Drug Screening Assays, Antitumor<br/>Drug Synergism<br/>Injections, Intraperitoneal<br/>Male<br/>Neovascularization, Pathologic--drug therapy<br/>O-(Chloroacetylcarbamoyl)fumagillol<br/>Random Allocation<br/>Rats<br/>Sesquiterpenes--administration & dosage<br/>Urinary Bladder Neoplasms--blood supply